Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with pointcheck: a portable non-invasive neutropenia analyzer

Active Project Grant Awarded Last action

Award ID
R44CA228920
Recipient
Awarding agency
Obligated
$9,800,642

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 92% complete
Originally
Funding
  • $8,994,640.00 Federal
  • $806,002.00 Non-federal
Place of performance
Cambridge, MA 02139, USA

Award details come from USAspending.gov.

Transactions

Action Federal Non-federal Date
Amendment $991,877 $0
Amendment $1,802,488 $0
Amendment $1,702,979 $0
Amendment $1,702,979 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $806,002 $0
Amendment $806,002 $806,002
Original award $1,182,313 $0

Quick answers

Who received award R44CA228920?

R44CA228920 was awarded to Leuko Labs, Inc. by National Cancer Institute (National Institutes of Health) on July 12, 2018.

How much is award R44CA228920 worth?

$9,800,642 has been obligated on R44CA228920: $8,994,640 in federal funding and $806,002 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award